论文部分内容阅读
胸腔积液通常是一些疾病进展过程中的并发症,常见疾病包括心衰、感染、恶性肿瘤等。恶性胸腔积液(malignant pleural effusions,MPEs)是由恶性肿瘤引起的胸腔积液。目前对MPEs的了解,包括其诊断、治疗方面已经取得了巨大进步。特异性分子标记物检测、危险度分级及胸腔导管介入术逐步发展,并可能在未来成为诊疗标准。MPEs诊治方法的进步给临床工作带来了新的希望。
Pleural effusion is usually a complication in the progression of some diseases. Common diseases include heart failure, infection, malignancy and the like. Malignant pleural effusions (MPEs) are pleural effusions caused by malignant tumors. At present, the understanding of MPEs, including its diagnosis and treatment, has made great strides. Specific molecular markers detection, risk grading and thoracic catheterization gradually developed and may become the standard of care in the future. Advances in the treatment of MPEs have brought new hope to clinical work.